{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T07:18:52Z","timestamp":1764919132446,"version":"3.46.0"},"reference-count":21,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["tjod"],"DOI":"10.4274\/tjod.galenos.2025.10662","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T13:06:49Z","timestamp":1764680809000},"source":"Crossref","is-referenced-by-count":0,"title":["Adjuvant radiotherapy for FIGO 2023 stage IC endometrial carcinoma"],"prefix":"10.4274","author":[{"given":"Alper","family":"Kahvecio\u011flu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sezin","family":"Y\u00fcce Sar\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melis","family":"G\u00fcltekin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ecem","family":"Yi\u011fit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafer","family":"Ar\u0131k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alp","family":"Usub\u00fct\u00fcn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Utku","family":"Akg\u00f6r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derman","family":"Ba\u015faran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nejat","family":"\u00d6zg\u00fcl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferah","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","unstructured":"1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49.","journal-title":"CA Cancer J Clin"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Leon-Castillo","year":"2020","unstructured":"2. Leon-Castillo A, de Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol. 2020;38:3388-97.","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Genome Atlas Research Network","year":"2013","unstructured":"3. Cancer Genome Atlas Research Network; Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67-73.","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","unstructured":"4. Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Can-cer. 2021;31:12-39.","journal-title":"Int J Gynecol Can-cer"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.prro.2022.09.002","article-title":"Ra-diation therapy for endometrial cancer: an American society for radiation oncology clinical practice guideline","volume":"13","author":"Harkenrider","year":"2023","unstructured":"5. Harkenrider MM, Abu-Rustum N, Albuquerque K, Bradfield L, Bradley K, Dolinar E, et al. Ra-diation therapy for endometrial cancer: an American society for radiation oncology clinical practice guideline. Pract Radiat Oncol. 2023;13:41-65.","journal-title":"Pract Radiat Oncol"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Mills KA, Lopez H, Sun L, Cripe JC, Litz T, Thaker PH, et al. Type II endometrial cancers with minimal, non-invasive residual disease on final pathology: what should we do next? Gyne-col Oncol Rep. 2019;29:20-4.","DOI":"10.1016\/j.gore.2019.05.007"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, et al, Endometri-al Cancer Staging Subcommittee FWsCC. FIGO staging of endometrial cancer: 2023. J Gy-necol Oncol. 2023;34:e85.","DOI":"10.3802\/jgo.2023.34.e85"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ygyno.2007.05.044","article-title":"Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma","volume":"107","author":"Thomas","year":"2007","unstructured":"8. Thomas MB, Mariani A, Cliby WA, Keeney GA, Podratz KC, Dowdy SC. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gy-necol Oncol. 2007;107:186-9.","journal-title":"Gy-necol Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ygyno.2005.06.012","article-title":"Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adju-vant platinum-based chemotherapy","volume":"98","author":"Kelly","year":"2005","unstructured":"9. Kelly MG, O'Malley D M, Hui P, McAlpine J, Yu H, Rutherford TJ, et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adju-vant platinum-based chemotherapy. Gynecol Oncol. 2005;98:353-9.","journal-title":"Gynecol Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijrobp.2012.03.011","article-title":"The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell en-dometrial cancer","volume":"85","author":"Barney","year":"2013","unstructured":"10. Barney BM, Petersen IA, Mariani A, Dowdy SC, Bakkum-Gamez JN, Haddock MG. The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell en-dometrial cancer. Int J Radiat Oncol Biol Phys. 2013;85:109-15.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1136\/ijgc-2020-001379","article-title":"Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium","volume":"30","author":"Nasioudis","year":"2020","unstructured":"11. Nasioudis D, Roy AG, Ko EM, Cory L, Giuntoli Ii RL, Haggerty AF, et al. Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium. Int J Gy-necol Cancer. 2020;30:1089-94.","journal-title":"Int J Gy-necol Cancer"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1097\/IGC.0b013e31822e7588","article-title":"Role of adjuvant chemo-therapy in patients with early stage uterine papillary serous cancer","volume":"21","author":"Mahdavi","year":"2011","unstructured":"12. Mahdavi A, Tajalli TR, Dalmar A, Vasilev SA, Lentz SE, Berman ML. Role of adjuvant chemo-therapy in patients with early stage uterine papillary serous cancer. Int J Gynecol Cancer. 2011;21:1436-40.","journal-title":"Int J Gynecol Cancer"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ygyno.2007.01.041","article-title":"Out-comes in surgical stage I uterine papillary serous carcinoma","volume":"105","author":"Havrilesky","year":"2007","unstructured":"13. Havrilesky LJ, Secord AA, Bae-Jump V, Ayeni T, Calingaert B, Clarke-Pearson DL, et al. Out-comes in surgical stage I uterine papillary serous carcinoma. Gynecol Oncol. 2007;105:677-82.","journal-title":"Gynecol Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.ygyno.2003.08.027","article-title":"Uterine papillary se-rous carcinoma: comparisons of outcomes in surgical Stage I patients with and without ad-juvant therapy","volume":"91","author":"Huh","year":"2003","unstructured":"14. Huh WK, Powell M, Leath CA, Straughn JM, Cohn DE, Gold MA, et al. Uterine papillary se-rous carcinoma: comparisons of outcomes in surgical Stage I patients with and without ad-juvant therapy. Gynecol Oncol. 2003;91:470-5.","journal-title":"Gynecol Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ygyno.2012.12.026","article-title":"Vaginal brachy-therapy for early stage uterine papillary serous and clear cell endometrial cancer","volume":"129","author":"Townamchai","year":"2013","unstructured":"15. Townamchai K, Berkowitz R, Bhagwat M, Damato AL, Friesen S, Lee LJ, et al. Vaginal brachy-therapy for early stage uterine papillary serous and clear cell endometrial cancer. Gynecol Oncol. 2013;129:18-21.","journal-title":"Gynecol Oncol"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Dallaire Nantel L, Renaud MC, Gregoire J, Sebastianelli A, Plante M. High-grade endometrial carcinoma limited to the endometrium or a polyp: is adjuvant treatment necessary? Int J Gynecol Cancer. 2021;31:1335-40.","DOI":"10.1136\/ijgc-2021-002771"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ygyno.2013.10.010","article-title":"Early stage papillary serous or clear cell carcinoma confined to or involving an endometrial polyp: outcomes with and without adjuvant therapy","volume":"131","author":"Chang-Halpenny","year":"2013","unstructured":"17. Chang-Halpenny CN, Natarajan S, Hwang-Graziano J. Early stage papillary serous or clear cell carcinoma confined to or involving an endometrial polyp: outcomes with and without adjuvant therapy. Gynecol Oncol. 2013;131:598-603.","journal-title":"Gynecol Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/PGP.0000000000000235","article-title":"Clinical significance of positive pelvic washings in uterine papillary serous carcinoma confined to an endometrial polyp","volume":"35","author":"Hanley","year":"2016","unstructured":"18. Hanley KZ, Fadare O, Fisher KE, Atkins KA, Mosunjac MB. Clinical significance of positive pelvic washings in uterine papillary serous carcinoma confined to an endometrial polyp. Int J Gynecol Pathol. 2016;35:249-55.","journal-title":"Int J Gynecol Pathol"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Seagle BL, Alexander AL, Lantsman T, Shahabi S. Prognosis and treatment of positive peri-toneal cytology in early endometrial cancer: matched cohort analyses from the National Cancer Database. Am J Obstet Gynecol. 2018;218:329.e1-15.","DOI":"10.1016\/j.ajog.2017.11.601"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ygyno.2017.03.011","article-title":"Prognostic significance of peri-toneal cytology in low-intermediate risk endometrial cancer","volume":"145","author":"Scott","year":"2017","unstructured":"20. Scott SA, van der Zanden C, Cai E, McGahan CE, Kwon JS. Prognostic significance of peri-toneal cytology in low-intermediate risk endometrial cancer. Gynecol Oncol. 2017;145:262-8.","journal-title":"Gynecol Oncol"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Tate K, Yoshida H, Ishikawa M, Uehara T, Ikeda SI, Hiraoka N, et al. Prognostic factors for pa-tients with early-stage uterine serous carcinoma without adjuvant therapy. J Gynecol Oncol. 2018;29:e34.","DOI":"10.3802\/jgo.2018.29.e34"}],"container-title":["Journal of Turkish Society of Obstetric and Gynecology"],"original-title":[],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:45:32Z","timestamp":1764917132000},"score":1,"resource":{"primary":{"URL":"https:\/\/tjoddergisi.org\/articles\/adjuvant-radiotherapy-for-figo-2023-stage-ic-endometrial-carcinoma\/doi\/tjod.galenos.2025.10662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":21,"URL":"https:\/\/doi.org\/10.4274\/tjod.galenos.2025.10662","relation":{},"ISSN":["1307-699X","2149-9330"],"issn-type":[{"type":"print","value":"1307-699X"},{"type":"electronic","value":"2149-9330"}],"subject":[],"published":{"date-parts":[[2025,12,2]]}}}